Syndax Pharmaceuticals Inc (1T3)

Currency in EUR
8.6000
-0.1500(-1.71%)
Delayed Data·
1T3 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1T3 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.60008.6000
52 wk Range
7.250020.6000
Key Statistics
Bid/Ask
8.60 / 8.95
Prev. Close
8.75
Open
8.6
Day's Range
8.6-8.6
52 wk Range
7.25-20.6
Volume
-
Average Volume (3m)
14
1-Year Change
-56.03%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1T3 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Syndax Pharmaceuticals Inc Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Compare 1T3 to Peers and Sector

Metrics to compare
1T3
Peers
Sector
Relationship
P/E Ratio
−2.7x−1.9x−0.5x
PEG Ratio
0.15−0.010.00
Price/Book
4.1x3.1x2.6x
Price / LTM Sales
20.2x67.0x3.3x
Upside (Analyst Target)
-293.6%42.4%
Fair Value Upside
Unlock30.1%7.2%Unlock

Earnings

Latest Release
May 05, 2025
EPS / Forecast
-0.98 / --
Revenue / Forecast
20.04M / --
EPS Revisions
Last 90 days

1T3 Income Statement

People Also Watch

267.80
AVAV
-0.22%
23.97
VCYT
-2.04%
19.22
URGN
+1.69%
16.75
SRPT
+5.81%
84.66
RYTM
-1.13%

FAQ

What Stock Exchange Does Syndax Pharmaceuticals Inc Trade On?

Syndax Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Syndax Pharmaceuticals Inc?

The stock symbol for Syndax Pharmaceuticals Inc is "1T3."

What Is the Syndax Pharmaceuticals Inc Market Cap?

As of today, Syndax Pharmaceuticals Inc market cap is 752.42M.

What Is Syndax Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Syndax Pharmaceuticals Inc EPS (TTM) is -3.86.

From a Technical Analysis Perspective, Is 1T3 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Syndax Pharmaceuticals Inc Stock Split?

Syndax Pharmaceuticals Inc has split 0 times.

How Many Employees Does Syndax Pharmaceuticals Inc Have?

Syndax Pharmaceuticals Inc has 270 employees.

What is the current trading status of Syndax Pharmaceuticals Inc (1T3)?

As of 31 Jul 2025, Syndax Pharmaceuticals Inc (1T3) is trading at a price of 8.60, with a previous close of 8.75. The stock has fluctuated within a day range of 8.60 to 8.60, while its 52-week range spans from 7.25 to 20.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.